
==== Front
Arch Virol
Arch. Virol
Archives of Virology
0304-8608 1432-8798 Springer-Verlag Vienna 

2845889
BF01310997
10.1007/BF01310997
Original Papers
In vitro activity of R 61837, a new antirhinovirus compound
Andries K.  Dewindt B.  De Brabander M.  Stokbroekx R.  Janssen P. A. J.  grid.419619.20000000406230341Janssen Research Foundation, Beerse, Belgium 
1988 
101 3 155 167
3 6 1988 3 6 1988 © Springer-Verlag 1988This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.Summary
R 61837 or 3-methoxy-6-[4-(3-methylphenyl)-1-piperazinyl]pyridazine is a new and potent inhibitor of rhinoviruses at concentrations not inhibitory to HeLa cell growth. Different rhinovirus serotypes varied widely in their susceptibility to the antiviral agent. The MICs for 50% CPE reduction ranged from 0.004 to 15 µg/ml. The yields of the most susceptible serotypes were reduced by a factor of 1,000 to 10,000 after single round high multiplicity infections in presence of low concentrations of the compound. The inactivation of some but not all serotypes in a time-, concentration- and temperature-dependent way by R 61837 indicated a direct interaction between the drug and the viral particles. The antiviral activity of the compound was confirmed in the human target cells for rhinoviruses by experiments using nasal polyp explant cultures.

Keywords
HeLa CellTarget CellPotent InhibitorDirect InteractionViral Particleissue-copyright-statement© Springer-Verlag 1988
==== Refs
References
1. Al-Nakib W  Willman J  Higgins PG  Tyrrell DAJ  Shepherd WM  Freestone DS   Failure of intranasally administered 4′,6-dichloroflavan to protect against rhinovirus infection in man Arch Virol 1987 92 255 260 3545152 
2. Al-Nakib W  Higgins PG  Tyrrell DAJ  Barrow IG  Taylor N  Andries K   Tolerance and prophylactic efficacy of a new antirhinovirus compound, R 61837 Proceedings of the VIIth International Congress of Virology, Edmonton 1987 Ottawa National Research Council Canada 217 
3. Bauer DJ  Selway JWT  Batchelor JF  Tisdale M  Caldwell IC  Young DAB   4′,6-dichloroflaven (BW 683 C), a new anti-rhinovirus compound Nature 1981 292 369 370 6265792 
4. Couch RB   The common cold: control? J Infect Dis 1984 150 167 173 6206168 
5. Fox MP  Otto MJ  McKinlay MA   Prevention of rhinovirus and poliovirus uncoating by WIN 51711, a new antiviral drug Antimicrob Agents Chemother 1986 30 110 116 3019232 
6. Groelke JW  Coalson JJ  Baseman JB   Growth requirements of ferret tracheal epithelial cells in primary culture Proc Soc Exp Biol Med 1985 179 309 317 3889927 
7. hamory BH  Hendley JO  Gwaltney JM Jr   Rhinovirus growth in nasal polyp organ culture Proc Soc Exp Biol Med 1977 155 577 582 197539 
8. Hamparian VV  Colonno RJ  Cooney MK  Dick EC  Gwaltney JM  Hughes JH  Jordan WS  Kapikian AZ  Mogabgab WJ  Monto A  Phillips CA  Reuckert RR  Schieble JH  Stott EJ  Tyrrell DAJ   A collaborative report: Rhinoviruses—extension of the numbering system from 89 to 100 Virology 1987 159 191 192 3037780 
9. Ishitsuka H  Ninomya YN  Ohsawa C  Fujiu M  Suhura Y   Direct and specific inactivation of rhinovirus by chalcone Ro 09-410 Antimicrob Agents Chemother 1982 22 617 621 6295261 
10. Kenny MT  Dulworth JK  Bargar TM  Torney HL  Graham MC  Manelli AM   In vitro antiviral activity of the 6-substituted 2-(3′-4′-dichlorophenoxy)-2H-pyrano[2,3-b]pyridines MDL 20,610, MDL 20,646, and MDL 20,957 Antimicrob Agents Chemother 1986 30 516 518 3593475 
11. Ninomya Y  Aoyama M  Umeda I  Suhara Y  Ishitsuka H   Comparative studies on the modes of action of the antirhinovirus agents Ro 09-410, Ro 09-0179, RMI-15,731, 4′,6-dichloroflavan, and enviroxime Antimicrob Agents Chemother 1985 27 595 599 2988431 
12. Lechner JF  Haugen A  McClendon IA  Pettis EW   Clonal growth of normal adult human bronchial epithelial cells in a scrum-free medium In Vitro 1982 18 633 643 7141447 
13. Otto MJ  Fox MP  Fancher MJ  Kuhrt MF  Diana GD  McKinlay MA   In vitro activity of WIN51711, a new broad-spectrum antipicornavirus drug Antimicrob Agents Chemother 1985 27 883 886 2992365 
14. Phillpotts RJ  Wallace J  Tyrrell DAJ  Freestone DS  Shepherd WM   Failure of oral 4′-6-dichloroflavan to protect against rhinovirus in man Arch Virol 1983 75 115 121 6338868 
15. Phillpotts RJ  Higgins PG  Willman JS  Tyrrell DAJ  Lenox-Smith I   Evaluation of the antirhinovirus chalcone Ro 09-0415 given orally to volunteers J Antimicrob Chemother 1984 14 403 409 6094423 
16. Reed SE   Collier JH  Oxford J   The assessment of antirhinovirus compounds with clinical potential Developments in antiviral chemotherapy 1980 London Academic Press 157 172 
17. Selway JWT   Antiviral activity of flavones and flavans Prog Clin Biol Res 1986 213 521 526 3012583 
18. Tisdale M  Selway JWT   Effect of dichloroflavan (BW 683 C) on the stability and uncoating of rhinovirus type 1B J Antimicrob Chemother 1984 14 Suppl A 97 105 
19. Zerial A  Werner GH  Phillpotts RJ  Willmann JS  Higgins PG  Tyrrell DAJ   Studies on 44 081 R.P., a new antirhinovirus compound, in cell cultures and in volunteers Antimicrob Agents Chemother 1985 27 846 850 2990329

